TY - JOUR
T1 - Effect of menthone on the in vitro percutaneous absorption of tamoxifen and skin reversibility
AU - Zhao, Kaidi
AU - Singh, Somnath
AU - Singh, Jagdish
N1 - Funding Information:
We acknowledge the financial support from the US Department of Defense grant # DSWA 01-97-1-0011.
PY - 2001/5/21
Y1 - 2001/5/21
N2 - The effect of penetration enhancer (i.e., 1, 2, 3 and 5% menthone in combination with 50% ethanol (EtOH)) was investigated on the in vitro percutaneous absorption of tamoxifen, and post-recovery epidermal permeability after removal of the above enhancer. The flux of tamoxifen with menthone in combination with 50% EtOH was significantly greater (P <0.05) than the control (50% EtOH). The flux of tamoxifen increased with increasing concentrations of menthone. The post-recovery flux through enhancer exposed epidermis was significantly decreased (P <0.05) as compared to pre-recovery. However, post-recovery flux of tamoxifen through the enhancer-exposed epidermis did not completely recover to the baseline (i.e., post-recovery flux through phosphate buffered saline, pH 7.4 treated epidermis).
AB - The effect of penetration enhancer (i.e., 1, 2, 3 and 5% menthone in combination with 50% ethanol (EtOH)) was investigated on the in vitro percutaneous absorption of tamoxifen, and post-recovery epidermal permeability after removal of the above enhancer. The flux of tamoxifen with menthone in combination with 50% EtOH was significantly greater (P <0.05) than the control (50% EtOH). The flux of tamoxifen increased with increasing concentrations of menthone. The post-recovery flux through enhancer exposed epidermis was significantly decreased (P <0.05) as compared to pre-recovery. However, post-recovery flux of tamoxifen through the enhancer-exposed epidermis did not completely recover to the baseline (i.e., post-recovery flux through phosphate buffered saline, pH 7.4 treated epidermis).
UR - http://www.scopus.com/inward/record.url?scp=0035927198&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035927198&partnerID=8YFLogxK
U2 - 10.1016/S0378-5173(01)00640-8
DO - 10.1016/S0378-5173(01)00640-8
M3 - Article
C2 - 11337177
AN - SCOPUS:0035927198
VL - 219
SP - 177
EP - 181
JO - International Journal of Pharmaceutics
JF - International Journal of Pharmaceutics
SN - 0378-5173
IS - 1-2
ER -